The global cervical cancer treatment market size is expected to reach USD 11.74 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030. Increased treatment penetration and rising disease incidence are projected to drive the market growth over the next few years. Although, sexually transmitted HPV is a major cause, the disease can also be triggered by other factors, such as oral contraceptives, multiple sexual partners, smoking, and HIV infection. There are more than 100 strains of HPV, 13 of which are high-risk or cancerous. Squamous cell carcinoma is the most common type and it accounts for nearly 85% of the overall cases.
The differentiation between squamous cell carcinoma and adenocarcinoma is based on the histology, as observed under the microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of squamous and glandular tissues. Products for cervical cancer can be broadly classified into prevention and treatment. Preventive options involve vaccines against HPV. Currently, there are two commercial vaccines - Gardasil and Cervarix. Treatment options include biologics, such as Avastin and generics like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin, and doxorubicin. The development of targeted therapeutics with improved efficacy and reduced cost remains a key unmet need of this market. Nevertheless, expanding focus on the research and development in oncology, including cervical cancer, indicate a promising future for this market.
This product will be delivered within 1-3 business days.
The differentiation between squamous cell carcinoma and adenocarcinoma is based on the histology, as observed under the microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of squamous and glandular tissues. Products for cervical cancer can be broadly classified into prevention and treatment. Preventive options involve vaccines against HPV. Currently, there are two commercial vaccines - Gardasil and Cervarix. Treatment options include biologics, such as Avastin and generics like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin, and doxorubicin. The development of targeted therapeutics with improved efficacy and reduced cost remains a key unmet need of this market. Nevertheless, expanding focus on the research and development in oncology, including cervical cancer, indicate a promising future for this market.
Cervical Cancer Treatment Market Report Highlights
- Squamous cell carcinoma type dominated the market and accounted for the largest revenue share of 71.1% in 2023. This growth is attributed to persistent infection with high-risk human papillomavirus (HPV) subtypes, mainly HPV 16 and 18, which account for most cases.
- Chemotherapy treatment led the market and accounted for the largest revenue share of 33.9% in 2023. This growth is attributed to the advancements in drug development that have significantly enhanced treatment options for cervical adenocarcinoma.
- Hospitals & clinics segment dominated the market and accounted for the largest revenue share of 65.0% in 2023. This growth is attributed to the enhanced delivery procedures in hospitals & clinics with offerings such as targeted therapy, radiation therapy, immunotherapy, minimally invasive surgeries, and many other methods.
- The North America cervical cancer treatment market dominated the global market and accounted for the largest revenue share of 39.4% in 2023.
The leading players in the Cervical Cancer Treatment market include:
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Eli Lilly and Company.
- Novartis AG
- AstraZeneca
- GSK plc.
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Cervical Cancer Treatment Market Variables, Trends, & Scope
Chapter 4. Cervical Cancer Treatment Market: Type Estimates & Trend Analysis
Chapter 5. Cervical Cancer Treatment Market: Treatment Estimates & Trend Analysis
Chapter 6. Cervical Cancer Treatment Market: End Use Estimates & Trend Analysis
Chapter 7. Cervical Cancer Treatment Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
The leading players in the Cervical Cancer Treatment market include:- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Eli Lilly and Company.
- Novartis AG
- AstraZeneca
- GSK plc.
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 8.16 Billion |
| Forecasted Market Value ( USD | $ 11.74 Billion |
| Compound Annual Growth Rate | 5.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
